Latest Content
Apr 03 - 2024
As part of Evaluate’s partnership with Galen Growth, we bring you their latest report on Digital Health Innovation in US Health Systems, built using data from HealthTech Alpha.
In the vast and complex US healthcare system, it’s challenging for all types...
Read More
Mar 20 - 2024
Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements and a notable IPO. This revival, though less conspicuous than obesity’s, emerges from years of underinvestment, resulting in a landscape filled...
Read More
Feb 23 - 2024
Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma:
Pfizer acquired Seagen for $43 billion
AbbVie invested over $10 billion in ImmunoGen
Merck committed $4 billion upfront, with a potential total...
Read More
No posts found
More content
Loading...